Mohab Ibrahim, MD, PhD

Associate Professor, Anetshesiology

Links

Biography

I have been interested in developing ways to understand and manage acute and chronic pain. I geared my education towards that goal. After finishing my undergraduate in biochemistry, I obtained my master's and a doctorate in pharmacology and toxicology with emphasis on neuropathic pain and cannabinoids. I then joined medical school. After my surgical prelim year and a residency in anesthesiology, I completed a fellowship in chronic pain management. My goal is to research clinical problems about pain we face as pain physicians in a laboratory then translate the findings to the clinic. My ultimate goal is to find complementary methods to manage pain and decrease reliance on opioids.

Cancer Focus

Cancer is one of the most profound medical conditions. It is a multi-dimensional condition. Controlling pain in cancer patients has been shown to prolong life and improve it. I focus my cancer research on the pain component associated with cancer and cancer metastasis. My approach is to collaborate with other specialties, mainly pharmacology and oncology, to identify clinically difficult conditions to manage, tackle such conditions in a laboratory setting, then translate our findings to clinical practice. Ultimately, I hope to find ways to manage cancer pain with less reliance on opioids. Cancer is a multi-dimensional condition and addressing cancer is similarly a multimodal approach.

Research Program Role

Clinical and Translational Oncology Program

Display Name
Mohab Ibrahim, MD, PhD

Publications

Martin LF, Patwardhan AM, Jain SV, Salloum MM, Freeman J, Khanna R, Gannala P, Goel V, Jones-MacFarland FN, Killgore WD, et al. 2021. Evaluation of green light exposure on headache frequency and quality of life in migraine patients: A preliminary one-way cross-over clinical trial. Cephalalgia. 41:135–147. doi:10.1177/0333102420956711.

Martin L, Porreca F, Mata EI, Salloum M, Goel V, Gunnala P, Killgore WDS, Jain S, Jones-MacFarland FN, Khanna R, et al. 2020 Nov. Green Light Exposure Improves Pain and Quality of Life in Fibromyalgia Patients: A Preliminary One-Way Crossover Clinical Trial. Pain Med. doi:10.1093/pm/pnaa329.

Zhang H, Lund DM, Ciccone HA, Staatz WD, Ibrahim MM, Largent-Milnes TM, Seltzman HH, Spigelman I, Vanderah TW. 2018. Peripherally restricted cannabinoid 1 receptor agonist as a novel analgesic in cancer-induced bone pain. Pain. 159:1814–1823. doi:10.1097/j.pain.0000000000001278.

Ibrahim MM, Patwardhan A, Gilbraith KB, Moutal A, Yang X, Chew LA, Largent-Milnes T, Malan TP, Vanderah TW, Porreca F, et al. 2017. Long-lasting antinociceptive effects of green light in acute and chronic pain in rats. Pain. 158:347–360. doi:10.1097/j.pain.0000000000000767.

Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodorova A, Davar G, Makriyannis A, Vanderah TW, Mata HP, et al. 2005. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A. 102:3093–8. doi:10.1073/pnas.0409888102.

Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, et al. 2003. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A. 100:10529–33. doi:10.1073/pnas.1834309100.